0000000000408708

AUTHOR

Giovanni Grimaldi

0000-0002-1107-2451

showing 4 related works from this author

High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study

2018

The aim of this multicenter study was to investigate the prognostic impact of residual T1 high-grade (HG)/G3 tumors at re-transurethral resection (TUR of bladder tumor) in a large multi-institutional cohort of patients with primary T1 HG/G3 bladder cancer (BC).

MaleTime Factorsmedicine.medical_treatment:Medicina Básica [Ciências Médicas]Treatment outcomeBladder cancer; High risk; High-grade; Second look resection; Transurethral resection of bladder tumor; Aged; Aged 80 and over; Carcinoma Transitional Cell; Cystectomy; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence Local; Prognosis; Progression-Free Survival; Recurrence; Regression Analysis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Surgical Procedures030232 urology & nephrologySettore MED/24 - Urologia0302 clinical medicineRecurrenceHigh-grade80 and overAged 80 and overTransurethral resection of bladder tumorCARCINOMA TRANSITIONAL CELLHigh riskBladder cancerFollow up studiesMiddle AgedPrognosisProgression-Free Survival3. Good healthScholarshipTreatment OutcomeLocal030220 oncology & carcinogenesisCiências Médicas::Medicina BásicaUrinary Bladder NeoplasmDisease ProgressionRegression AnalysisUrologic Surgical ProceduresFemaleSecond look resectionHumanmedicine.medical_specialtyTime FactorPrognosiUrologyBladder cancer; High risk; High-grade; Second look resection; Transurethral resection of bladder tumorCystectomyRegression AnalysiDisease-Free SurvivalResectionFollow-Up StudieCystectomy03 medical and health sciencesbladder cancer; high risk; high-grade; second look resection; transurethral resection of bladder tumor; aged; aged 80 and over; carcinoma transitional cell; cystectomy; disease progression; disease-free survival; female; follow-up studies; humans; malemedicineHumansProgression-free survivalAgedCarcinoma Transitional CellScience & Technologybusiness.industryGeneral surgeryDisease progressionCarcinomaNeoplasm RecurrenceUrinary Bladder NeoplasmsUrologic Surgical ProcedureTransitional CellTransurethral resection of bladder tumor.Neoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer

2018

PURPOSE: The body mass index (BMI) may be associated with an increased incidence and aggressiveness of urological cancers. In this study, we aimed to evaluate the impact of the BMI on survival in patients with T1G3 non-muscle-invasive bladder cancer (NMIBC). METHODS: A total of 1155 T1G3 NMIBC patients from 13 academic institutions were retrospectively reviewed and patients administered adjuvant intravesical Bacillus Calmette-Guérin (BCG) immunotherapy with maintenance were included. Multivariable Cox regression analysis was performed to identify factors predictive of recurrence and progression. RESULTS: After re-TURBT, 288 patients (27.53%) showed residual high-grade NMIBC, while 867 (82.8…

Malemedicine.medical_treatmentPrognosis.030232 urology & nephrologyComorbidityGastroenterologySettore MED/24 - Urologia0302 clinical medicineBladder cancer; Body mass index; Obesity; PrognosisMedicineBody mass indexAged 80 and overHazard ratioBladder cancerCystoscopyMiddle AgedPrognosisTumor BurdenAdministration IntravesicalEditorialTransitional cell carcinomaChemotherapy Adjuvant030220 oncology & carcinogenesisBCG VaccineDisease ProgressionFemalemedicine.medical_specialtyPrognosiUrologyCystectomyDisease-Free SurvivalCystectomy03 medical and health sciencesAdjuvants ImmunologicInternal medicineHumansObesityMortalityAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCancer stagingCarcinoma Transitional CellBladder cancer; Body mass index; Obesity; Prognosis; UrologyScience & TechnologyBladder cancerbusiness.industryProportional hazards modelmedicine.diseaseUrinary Bladder NeoplasmsConcomitantMultivariate AnalysisbusinessBody mass index
researchProduct

Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non–muscle-invasive Bladder Cancer

2018

The aim of this multicenter study was to investigate the prognostic role of neutrophil-to-lymphocyte ratio (NLR) and to validate the NLR cutoff of 3 in a large multi-institutional cohort of patients with primary T1 HG/G3 non-muscle-invasive bladder cancer (NMIBC).

High risk; High-grade; NLR; Progression; RecurrenceMaleNeutrophilsmedicine.medical_treatment030232 urology & nephrologySettore MED/24 - Urologia0302 clinical medicineRecurrenceHigh-gradeRecurrence.LymphocytesHigh risk; High-grade; NLR; Progression; Recurrence; Oncology; UrologyAged 80 and overProgressionHigh riskMiddle AgedPrognosis3. Good healthAdministration IntravesicalOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisCohortBCG VaccineDisease ProgressionFemaleNon muscle invasiveAdjuvantAdultmedicine.medical_specialtyUrologyUrologyCystectomyDisease-Free SurvivalNLRResection03 medical and health sciencesmedicineHumansLymphocyte CountNeutrophil to lymphocyte ratioAgedRetrospective StudiesScience & TechnologyBladder cancerbusiness.industryfungimedicine.diseaseConfidence intervalUrinary Bladder NeoplasmsMulticenter studyNeoplasm Recurrence LocalbusinessClinical Genitourinary Cancer
researchProduct

Predictors of residual T1 high grade on re-transurethral resection in a large multi-institutional cohort of patients with primary T1 high-grade/grade…

2018

The aim of this multi-institutional study was to identify predictors of residual high-grade (HG) disease at re-transurethral resection (reTUR) in a large cohort of primary T1 HG/Grade 3 (G3) bladder cancer patients. A total of 1155 patients with primary T1 HG/G3 bladder cancer from 13 academic institutions that underwent a reTUR within 6 weeks after first TUR were evaluated. Logistic regression analysis was performed to assess the association of predictive factors with residual HG at reTUR. Residual HG cancer was found in 288 (24.9%) of patients at reTUR. Patients presenting residual HG cancer were more likely to have carcinoma in situ (CIS) at first resection (p=25 kg/m2. On multivariable …

Bladder cancer; High-grade; Neutrophil-to-lymphocytes ratio; Re-transurethral resection; Oncologymedicine.medical_specialty030232 urology & nephrologyUrologyOverweightResidualLogistic regressionSettore MED/24 - Urologia03 medical and health sciences0302 clinical medicineRe-transurethral resectionHigh-grademedicinehigh-grade2. Zero hungerBladder cancerScience & Technologybusiness.industryCarcinoma in situBladder cancerCancerre-transurethral resectionmedicine.disease3. Good healthre-transurethral resection.Oncology030220 oncology & carcinogenesisConcomitantCohortbladder cancermedicine.symptomNeutrophil-to-lymphocytes ratiobusinessneutrophil-to-lymphocytes ratioResearch Paper
researchProduct